The Oncology Institute, Inc.
TOI
$3.76
$0.092.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.53% | 10.29% | 16.88% | 21.78% | 22.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.53% | 10.29% | 16.88% | 21.78% | 22.88% |
| Cost of Revenue | 19.58% | 5.39% | 19.92% | 29.49% | 31.40% |
| Gross Profit | 34.35% | 44.11% | 1.79% | -10.09% | -13.83% |
| SG&A Expenses | -3.46% | -10.81% | -11.86% | -5.39% | -2.79% |
| Depreciation & Amortization | 18.91% | 19.81% | 8.24% | -7.36% | 14.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.98% | 1.49% | 10.88% | 18.59% | 20.86% |
| Operating Income | 31.49% | 44.85% | 22.54% | 0.22% | -9.95% |
| Income Before Tax | -10.73% | 1.53% | 30.87% | 6.78% | 7.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.88% | 1.53% | 29.71% | 7.50% | 8.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.88% | 1.53% | 29.71% | 7.50% | 8.39% |
| EBIT | 31.49% | 44.85% | 22.54% | 0.22% | -9.95% |
| EBITDA | 36.64% | 50.69% | 26.05% | -0.77% | -9.53% |
| EPS Basic | 11.50% | 4.88% | 31.23% | 9.84% | 9.06% |
| Normalized Basic EPS | 11.00% | 22.49% | 35.34% | 6.15% | 7.19% |
| EPS Diluted | 11.71% | 4.55% | 30.77% | 7.31% | 10.53% |
| Normalized Diluted EPS | 11.00% | 22.49% | 35.34% | 6.15% | 7.19% |
| Average Basic Shares Outstanding | 24.69% | 3.86% | 2.98% | 2.80% | 0.85% |
| Average Diluted Shares Outstanding | 24.69% | 3.86% | 2.98% | 2.80% | 0.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |